Embolization Particle Market

Growing prevalence of cancer incidence is driving the market growth

Market CAGR for embolization particles is driven by the rising rates of cancer because particle embolization is an important advancement for the treatment of cancer and other malignancies. The increasing worldwide cancer incidence has influenced the development of the Embolization Particle industry. They are increasingly used to treat illnesses apart from cancer, such as vascular abnormalities and fibrosis. The market is being bolstered by factors such as the rapidly growing healthcare sector and the increasing attention paid by academic institutions to developing cutting-edge technological solutions for improved diagnostics and treatment modalities.

Demand for embolization particles is expected to rise due to the issues mentioned above in the future.

Additionally, minimally invasive methods, such as embolization particle therapy, are gaining popularity among patients and medical professionals, which bodes well for the future of the market for related products. The rise in cancer rates worldwide and the introduction of new types of Embolization Particles are factors that should help the market expand in the next years. Moreover, leading companies continually release cutting-edge, highly efficient products, which contributes to developing the embolization particle market. The embolization cancer market is anticipated to expand in the coming years due to increasing expenditure on research and development and industry leaders’ introduction of new products.

Governments and non-profit organizations are trying to raise public awareness of embolization cancer in some countries. Oncologists and other cancer specialists have recently been interested in embolization cancer research. Therefore, the increasing prevalence of embolization particles is fueling the expansion of the international market. For instance, Guerbet (FR0000032526 GBT) reports it's going more than treble its line of microcatheters and introducing a new line of guidewires, resulting in a wide range of interventional imaging and embolization solutions being offered.

As a result, the demand for embolization particles is predicted to grow throughout the forecasted time due to the rising cancer cases. Thus, the driving factor is the embolization particle market revenue.

The Global Embolization Particle Market Industry is projected to experience substantial growth over the next decade. With a market value of 0.78 USD Billion in 2024, it is expected to reach 2.8 USD Billion by 2035, indicating a robust expansion trajectory. The anticipated CAGR of 12.31% from 2025 to 2035 highlights the increasing demand for embolization particles driven by advancements in medical technology and rising patient awareness. This growth reflects the industry's potential to address the evolving needs of healthcare providers and patients alike.

The Global Embolization Particle Market Industry is experiencing growth due to the increasing prevalence of vascular diseases, including tumors and arteriovenous malformations. As healthcare systems worldwide recognize the need for effective treatment options, the demand for embolization particles is expected to rise. For instance, the market is projected to reach 0.78 USD Billion in 2024, reflecting a growing awareness of minimally invasive procedures. This trend is likely to continue as more patients seek alternatives to traditional surgical methods, thereby driving the market forward.

Regulatory support for innovative therapies is a key driver of the Global Embolization Particle Market Industry. Regulatory bodies are increasingly facilitating the approval process for new embolization products, which encourages manufacturers to invest in research and development. This supportive environment fosters innovation and enhances the availability of advanced embolization particles in the market. As a result, the industry is likely to witness a surge in product offerings, contributing to its overall growth and expansion in the foreseeable future.

Technological advancements in medical devices play a crucial role in the expansion of the Global Embolization Particle Market Industry. Innovations such as improved imaging techniques and the development of biocompatible materials enhance the efficacy and safety of embolization procedures. These advancements not only facilitate better patient outcomes but also encourage healthcare providers to adopt these technologies. As a result, the market is projected to grow significantly, with estimates suggesting a value of 2.8 USD Billion by 2035. This growth underscores the importance of continuous innovation in medical technology.

Growing awareness of minimally invasive procedures is significantly influencing the Global Embolization Particle Market Industry. Patients and healthcare professionals are increasingly recognizing the benefits of these techniques, which include reduced recovery times and lower complication rates. This shift in perception is driving demand for embolization particles as a preferred treatment option for various conditions. As the market evolves, it is anticipated that the adoption of these procedures will continue to rise, further propelling the industry's growth trajectory in the coming years.

The Global Embolization Particle Market Industry benefits from increasing investments in healthcare infrastructure, particularly in developing regions. Governments and private entities are focusing on enhancing healthcare services, which includes the procurement of advanced medical devices for embolization procedures. This investment trend is likely to improve access to treatment options, thereby expanding the market. With a projected CAGR of 12.31% from 2025 to 2035, the industry is poised for substantial growth as healthcare systems evolve to meet the rising demand for effective vascular treatments.

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American embolization particle market will dominate Due to the strong economy, the huge growth of the healthcare field, the rise in the number of people with cancer, and the fact that research institutions are putting more and more effort into updating technology to find new and better ways to diagnose and treat people. The market is also growing because hospitals have different layouts, and there are a lot of skilled healthcare workers.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: EMBOLIZATION PARTICLEMARKET SHARE BY REGION 2022 (USD Billion) 

Source: Secondary Research, Primary Research, Market Research Future Database, and Analyst Review

Europe’s embolization particle market accounts for the second-largest market share because of developments in healthcare provision, which have improved patients' access to diagnosis and treatment, and because of increased consumer knowledge of the medicines offered. Further, the embolization particle market held the largest market share, and the UK embolization particle market was the fastest-growing market in the European region.

 The Asia-Pacific embolization particle market is expected to grow at the fastest CAGR from 2023 to 2032 because more people need healthcare in developing countries like India. In addition, the government's focus on improving healthcare facilities and the surge in medical tourism is likely to fuel the expansion of the embolization particle market in this region. Moreover, China’s embolization particle market held the largest market share, and the Indian embolization particle market was the fastest-rising market in the Asia-Pacific region.

Leading market players are investing heavily in research and development to expand their product lines, which will help the embolization particle market grow even more. There are some strategies for action that market participants are implementing to increase their presence around the world's footprint, with important market developments including new product launches, contractual agreements and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the embolization particle industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics manufacturer use in the embolization particle industry to benefit clients and increase the market sector. In recent years, the embolization particle industry has offered some of the most significant technological advancements. Major players in the Embolization Particle market, including Guerbet, Terumo, BTG International Ltd, Boston Scientific Corporation, Medtronic, Sirtex, Merit Medical, and others, are attempting to grow market demand by investing in research and development operations.

Terumo has dedicated 100 years to “Contributing to Society through Healthcare” and is a leader in medical technology worldwide. With its headquarters in Tokyo and offices worldwide, Terumo employs more than 30,000 people to offer cutting-edge medical solutions in more than 160 nations and territories. The company has supported healthcare since its beginnings as a Japanese thermometer producer. Its broad range of goods now includes peritoneal dialysis treatments, blood transfusion systems, diabetic care, and solutions for vascular intervention and cardio surgery. It also includes technologies for blood transfusion and cell therapy.

The Cardiac and Vascular Company focuses on treating illnesses of the blood vessels throughout the body, including the vital organs of the heart and lungs. They offer oxygenators and heart-lung machines to maintain life in place of the heart and lungs during cardiac surgery, surgical grafts and stent-grafts to replace blood vessels damaged by disease, and interventional devices that allow treatment by accessing blood vessels through a catheter to treat regions of the body including the heart and brain. Terumo will continue to work to improve its value to patients, healthcare workers, and the general public.

In January 2023, Terumo Corporation (TSE: 4543) and Kyowa Kirin Co., Ltd. (TSE: 4151) collaborated to create the drug-device combination product "G-Lasta® Subcutaneous Injection 3.6 mg BodyPod".

Merit Medical Systems, Inc., a prominent producer, and distributor of unique disposable medical devices used in interventional, diagnostic, and therapeutic procedures, especially in cardiology, radiology, cancer, critical care, and endoscopy, was founded in 1987. Merit provides services to client hospitals worldwide with a domestic and international sales force and a clinical support team of more than 500 people, with offices in South Jordan, Utah. Pearland, Texas; Richmond, Virginia.

Aliso Viejo, California, Maastricht and Venlo, The Netherlands, Paris, France, Galway, Ireland, Beijing, China, Tijuana, Mexico, Joinville, Brazil, Ontario, Canada, Melbourne, Australia, Tokyo, Japan, Reading, the United Kingdom, Johannesburg, South Africa, and Singapore, Merit employs about 6,300 people worldwide.

To build long-term value for our customers, employees, shareholders, and communities, we must be outwardly focused and committed to providing an unforgettable experience. In March 2023, Merit Medical Systems announced that the SwiftNINJA Steerable Microcatheter product line had been widened. There are new lengths of 150 cm and a 2.4F distal diameter option with a low profile.